Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
复制标题
DOI：
10.1016/j.ccr.2005.10.001
复制
发表时间：
2005-11-01
期刊：
影响因子：
50.3
通讯作者：
Chinnaiyan, AM
中科院分区：
文献类型：
--
作者：
Varambally, S;Yu, JJ;Chinnaiyan, AM
在转录水平上对癌症进行分子分析已经成为常规。大规模分析癌症进展过程中的蛋白质组学改变是一项更艰巨的任务。在这里，我们采用高通量免疫印迹，以询问来自前列腺癌的组织提取物。我们确定了64种蛋白质在前列腺癌中相对于良性前列腺发生了改变，另外156种蛋白质在转移性疾病中发生了改变。对蛋白质组学改变和转录组学数据的概要进行了综合分析，揭示了蛋白质和转录水平之间仅48%-64%的一致性。重要的是，转移性和临床局限性前列腺癌之间的差异蛋白质组学改变一致映射到基因转录作为前列腺癌以及其他实体瘤的临床结果的预测因子。
Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis of proteomic alterations during cancer progression has been a more daunting task. Here, we employed high-throughput immunoblotting in order to interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that were altered in prostate cancer relative to benign prostate and 156 additional proteins that were altered in metastatic disease. An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed, revealing only 48%-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors.